COVID-19 and Nebulized Therapies

April 2, 2020

Attention: Midwest Allergy asthma patients

Recent data indicates that COVID-19 can persist in droplets in the air for 1 to 2 hours after nebulized therapies.  We are recommending that patients minimize use of nebulized therapies if possible.  If nebulized therapies are necessary, we recommend administering in a location that minimizes exposure to other household members.  We will continue to monitor this situation and update our patients as new information becomes available.   Please don’t hesitate to call with questions.

Additional information is available through the American Academy of Asthma, Allergy, and Immunology.